Defined infection history
Separate culture- or PCR-defined infection, clinician-diagnosed infection, recurrent viral or bacterial patterns, ENT anatomy, exposure, and an unclassified illness history.
PHENOTYPE · IMMUNE / BARRIER
Immune and barrier findings require separate measurement.
Within the active 61-person cohort, 25 profiles contain mapped immune, skin, or mucosal content and 36 remain unreported in this lane. Selected records include infection and anatomy, antibody-response testing, mixed laboratory panels, barrier or repair concerns, and illness-linked functional change. They do not form one uniform immune profile.
18 + 7 = 25positive-only + mixed source-mapped profiles; denominator 61
6 / 25mapped person-lane cells with a formal-record anchor
36 / 61unreported in this lane; missing is not negative
CLINICAL EVIDENCE MAP
Six layers prevent an “immune problem” label from replacing the actual evidence.
The same case may contribute to several layers. Each observation retains its source, timing, treatment context, and competing explanations.
Antibody and vaccine response
Immunoglobulins, vaccine history, pneumococcal serotype breadth, tetanus response, booster timing, repeat response, age, laboratory method, and immunology interpretation.
Inflammatory and cytokine assays
ESR, CRP, CBC, cytokines and other immune panels must retain collection timing, illness state, reference range, treatment context, and which values were normal.
Mucosal and epithelial barriers
Oral-tissue injury, local skin flares or fragility, ENT mucosa, GI tissue findings, and tissue-specific examination remain separate observations.
Bruising, healing and vascular signals
Bruising, wound repair, scar or skin fragility, hemostatic factors, endothelial or vasculitic history, fracture or mobility context, and co-findings.
Illness-linked functional change
Sleep, motor output, language access, bowel state, temperature, behavior, seizures or autonomic events may change around illness and recovery; direction and duration must be preserved.
WHAT THE CASES CURRENTLY SHOW
A signal worth standardized phenotyping—not a single established immune syndrome.
Selected records include limited pneumococcal serotype breadth, tetanus antibody results, and later booster or recheck context. Age, vaccine history, laboratory threshold, and specialist interpretation matter.
Some panels contain isolated or patchy outliers while several other cytokines were not elevated. Another history reports normal ESR, CRP, or IL-6 alongside other reported immune values.
Oral tissue injury, skin fragility or recurrent flares, bruising, wound-healing concerns, and selected vascular or hemostatic markers broaden the question beyond infection count alone.
Illness windows sometimes align with changes in bowel function, movement, sleep, seizure burden, temperature, or access to language. These are temporal anchors, not proof of an immune cause.
CROSS-CASE EVIDENCE ARCHITECTURE
The signal is distributed across records, tissues, and time—not contained in one person.
5 deep longitudinal packets spanning 4 age bands contribute to this research thread, while the full lane remains 25 source-mapped and 36 unreported of 61. The matrix preserves what is formal, reported, observed, controlled, and still hypothetical without publishing a person-level dossier.
- FFormal record, laboratory, or report
- RReported formal or clinical content
- PParent-observed chronology
- XInference or testable hypothesis
DomainSeparated evidence stackControl / competing explanationResearch question
Infection, anatomy & exposure
- F
Formal recordSelected records contain imaging, operative findings, organism testing, cultures, and interval examinations.
- R
Reported formalENT, respiratory, skin, and urinary infection histories are represented across separate profiles.
- P
Parent-observedFamilies describe different illness duration, treatment windows, and return-to-baseline patterns.
CONTROL
Reassuring interval examinations, hearing measures, and nonconfirmatory episodes remain visible beside confirmed infection or structural disease.
X · TEST NEXT
Separate organism, anatomy, exposure, treatment, barrier, and immune-response contributions prospectively.
Antibody response over time
- F
Formal recordSelected records contain serotype-specific pneumococcal testing and repeat response measurements.
- R
Reported formalEarlier titer summaries, vaccine or booster context, and specialist interpretation remain reported in other records.
- P
Parent-observedCaregiver-reported infection burden remains separate from the laboratory response.
CONTROL
Measured rises, mixed breadth, and variable later values prevent a simple present-versus-absent interpretation.
X · TEST NEXT
Use age-appropriate thresholds, verified vaccine dates, standardized pre/post timing, immunoglobulins, and clinical-immunology review.
Inflammation & hematology
- F
Formal recordCBCs, screening inflammatory markers, cytokine panels, and hemostatic testing contain both outlying and within-range components.
- R
Reported formalSome longitudinal laboratory trends remain reported or compiled pending primary-series reconciliation.
- P
Parent-observedIllness-linked functional change is described without a demonstrated immune mechanism.
CONTROL
Normal screening markers and normal components within mixed panels remain part of the evidence, not footnotes to an abnormal result.
X · TEST NEXT
Distinguish transient from reproducible change and test ordinary hematologic, infectious, medication, nutritional, and inflammatory explanations.
Barrier tissues & local repair
- F
Formal recordAvailable examination, tissue, procedural, and hemostatic records are uneven and system-specific.
- R
Reported formalClinical histories include oral, skin, bruising, healing, ENT, and GI concerns across different records.
- P
Parent-observedFamilies describe local flares, injury sensitivity, or variable recovery in different tissue compartments.
CONTROL
Mechanical injury, dermatologic disease, anatomy, connective-tissue co-findings, medication, and exposure remain active alternatives.
X · TEST NEXT
Measure epithelial integrity, local inflammation, hemostasis, connective tissue, and repair kinetics as distinct lanes.
Gut & mucosal interface
- F
Formal recordSeparate records pair substantial bowel, feeding, or tissue concerns with reassuring conventional inflammatory, malabsorption, or interval controls.
- R
Reported formalOther histories include localized mucosal-marker, motility, reflux, or allergy-related findings that are not interchangeable.
- P
Parent-observedFamilies describe exposure-linked GI change, bowel-state shifts, or improvement after trigger avoidance in different profiles.
CONTROL
Normal conventional studies do not erase symptoms, while an isolated local marker does not establish systemic inflammation or one cohort-wide GI mechanism.
X · TEST NEXT
Separate motility, allergy, nutrition, medication, infection, and local mucosal response with matched tissue and recovery measures.
Urinary, vascular & repair anchors
- F
Formal recordSeparate records contain urinalysis, culture, blood-count, coagulation, sleep, bone, or tissue measurements.
- R
Reported formalAdditional urinary, bruising, fracture, and wound histories remain record-pending or only partially reconciled.
- P
Parent-observedFatigue, heat sensitivity, pain, or recovery concerns add chronology but not a vascular diagnosis.
CONTROL
Culture-positive and nonconfirmatory urinary episodes, later reassuring results, and ordinary clinical explanations must remain separated.
X · TEST NEXT
Use the appropriate renal, hematologic, dermatologic, bone, and vascular differential rather than inferring one endothelial pathway.
Illness-linked function & recovery
- F
Formal recordOnly selected illness windows have contemporaneous laboratory, imaging, EEG, sleep, or procedure anchors.
- R
Reported formalSleep, bowel, movement, language, temperature, and seizure changes occur in different clinical histories.
- P
Parent-observedDirection, duration, completeness of recovery, and the resulting baseline vary across longitudinal accounts.
CONTROL
No-change windows, full recovery, medication effects, hydration, seizure, bowel, sleep, and endocrine explanations are required comparators.
X · TEST NEXT
Repeat the same measures across baseline, defined event, early response, resolution, and functional recovery.
Privacy and interpretation boundary: each row synthesizes separate records. Cells may come from different people. No row, column, or path should be read as one composite ASH1L phenotype. A normal control is part of the evidence—not a contradiction. A missing test is not a normal test.
PROPOSED RESOLUTION-KINETICS STUDY
A “failure to close” model must be tested as a curve—not inferred from an isolated result.
Experimental Ash1l work in macrophages motivates a negative-feedback question. The current human records do not establish persistent immune activation, primary immunodeficiency, trained immunity, or delayed resolution as an ASH1L mechanism.
- 01Stable baseline
Define the person’s usual function, current medications, exposure state, tissue findings, and clinically indicated laboratory baseline.
- 02Defined event
Name the organism, anatomy, exposure, injury, procedure, treatment, fever, hydration, and exact onset rather than using “flare” alone.
- 03Early response
Capture direction, magnitude, tissue compartment, vital signs, contemporaneous tests, and functional change with the same instruments.
- 04Resolution
Repeat the same measures as symptoms fall. In research, test cell-specific negative-feedback programs rather than inferring them from symptoms.
- 05Recovery
Document complete return, persistent change, recurrence, or a new baseline across sleep, bowel, movement, language, pain, and participation.
Returned to baseline
Preserve the recovery time and the normal comparator.
Persistent change
Reassess ordinary infectious, anatomic, neurologic, endocrine, GI, hematologic, medication, and tissue-specific causes.
Reproducible delayed resolution
Advance only a repeated, phase-matched signal to cell-specific mechanism and rescue experiments.
NORMAL ESR / CRP
Normal screens narrow; they do not close the differential.
ESR and CRP are nonspecific. Normal results can lower suspicion for some systemic inflammatory states, but they do not rule out localized tissue disease, every immune disorder, seizures, sleep-disordered breathing, bowel burden, celiac disease, arrhythmia or syncope, or endocrine and metabolic causes.
Open the clinician evidence boundary →EXPERIMENTAL BIOLOGY + HUMAN EVIDENCE BOUNDARY
ASH1L has testable immune and barrier functions in experimental systems.
The direct studies identify cell-specific pathways and measurable compartments. No published patient-derived study has yet connected heterozygous ASH1L-related disorder to a defined immune or barrier mechanism, prevalence estimate, biomarker, or treatment.
Macrophage / innate signaling
In Ash1l-silenced mouse macrophages, TLR stimulation produced increased IL-6/TNF signaling associated with reduced induction of Tnfaip3/A20 and altered NF-κB/MAPK regulation.
This is direct immune-lineage model evidence, not proof of persistent cytokine activation, immune deficiency, or autoimmunity in people with ASH1L-related disorder.
Xia et al., Immunity, 2013 ↗CD4 T-cell differentiation
Ash1l and lnc-Smad3 regulated Smad3-locus accessibility and regulatory T-cell polarization in experimental systems, with protection in a mouse colitis model.
The study is immune-lineage mechanism, not a clinical prevalence or treatment study in ASH1L families.
Xia et al., Nature Communications, 2017 ↗Hematopoietic stem cells
Ash1l-deficient mice showed impaired adult stem-cell quiescence, niche occupancy, and long-term self-renewal with altered Hox expression.
This does not establish cytokine-driven CBC skewing, cytopenia, immune deficiency, marrow disease, or leukemia risk in people with germline ASH1L variants.
Jones et al., JCI, 2015 ↗Epidermis and wound repair
A hypomorphic mouse model showed altered keratinocyte proliferation and differentiation, epidermal stratification, and wound re-epithelialization.
It supports an experimental skin-homeostasis question, not a universal human skin phenotype.
Li et al., Scientific Reports, 2017 ↗Sensory neuron–skin interface
In a psoriasis-like mouse model, sensory-neuron Ash1l haploinsufficiency increased excitability and activity-dependent miR-let-7b release, engaging dermal dendritic-cell TLR7 and the IL-23/IL-17 axis.
This specialized model does not establish psoriasis risk, vagal failure, or generalized autonomic or immune dysfunction in ASH1L-related disorder.
Du et al., British Journal of Pharmacology, 2024 ↗Human evidence boundary
Published human ASH1L-related disorder descriptions include feeding, GI, and selected hearing findings, but have not systematically established recurrent infection, cytokine dysregulation, or barrier disease.
Missing standardized assessment is not a negative finding; it also cannot be used to declare a recognized human immune or barrier phenotype.
Cordova et al., Genes, 2024 ↗RESEARCH-READY PHENOTYPING
Pair defined clinical events with repeatable immune and barrier measurements.
Define the event
Organism or syndrome, site, fever, culture or PCR, clinician diagnosis, exposure, treatment, duration, and return to baseline.
Interpret vaccine response
Age, vaccine series, baseline and post-booster timing, serotype-specific results, immunoglobulins, and clinical-immunology interpretation.
Repeat outside acute illness
When clinically appropriate, pair CBC and inflammatory or immune assays with a stable-state control rather than interpreting an isolated panel.
Examine the tissue
Skin, oral and ENT mucosa, wound history, GI context, photographs or pathology when clinically obtained, and relevant co-findings.